Real-World Characteristics and Treatment Patterns of Patients Treated with Talazoparib + Enzalutamide for Metastatic Castration- Resistant Prostate Cancer in the US Community Oncology Setting

Study identification

• EU PAS number:
  EUPAS1000000931
• Study ID:
  1000000931
• Official title and acronym:
  Real-World Characteristics and Treatment Patterns of Patients Treated with Talazoparib + Enzalutamide for Metastatic Castration- Resistant Prostate Cancer in the US Community Oncology Setting
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  No information provided.
• Study status:
  Planned

Research institutions and networks

No information provided.

Study timelines

Date when funding contract was signed

Planned:09/08/2024

Actual:09/08/2024

Study start date

Planned:30/04/2025

Date of final study report

Planned:31/12/2026

Sources of funding

More details on funding

No information provided.

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable